Ascletis' once-monthly GLP-1/GIP/GCGR triple agonist ASC37 shows 88% superior weight loss vs tirzepatide in obese mice, signaling a potential next‑generation obesity therapy
Executive summary: Ascletis announced that its triple peptide agonist ASC37 achieved an 88% greater relative body weight reduction compared to tirzepatide in a diet‑induced obese mouse model, with both once‑monthly subcutaneous and oral formulations slated for U.S. FDA submission. The data suggest ASC37 could exceed the efficacy of current GLP‑1/GIP dual agonists, potentially shifting market dynamics in the obesity drug sector.
Who is involved: Ascletis (biotech sponsor), its research team, the U.S. Food and Drug Administration (future regulator), and tirzepatide (the comparator drug from Eli Lilly).
Likely next: Ascletis will file IND packages with the FDA to initiate Phase I clinical trials; positive outcomes could lead to larger studies, partnership discussions, or licensing deals.
The company reported that ASC37 achieved an 88% greater relative body weight reduction compared to tirzepatide in a diet-induced obese mouse model, with both subcutaneous once‑monthly and oral formulations slated for U.S. FDA submission. The result suggests ASC37 could offer improved efficacy over existing dual‑agonist therapies, though translation to humans remains unproven. If successful, ASC37 could capture share in the growing GLP‑1‑based obesity market, which is projected to exceed $100 billion by 2030. Regulatory scrutiny will focus on safety and long‑term outcomes typical for peptide‑based metabolic agents.
Timeline
- — Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model (PR Newswire)
Analysis — what this means
Sectors affected
- Obesity therapeutics
- Biotechnology
- Pharmaceuticals
Regulatory implications
- FDA will review IND submissions for ASC37 subcutaneous and oral formulations